Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Ann Hematol ; 92(5): 699-705, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23328791

RESUMEN

The prognosis for patients with hematological malignancies (HMs) admitted to the intensive care unit (ICU) is poor. The objective of this study was to evaluate the clinical characteristics and hospital outcomes of critically ill patients with HMs admitted to an oncological ICU. This is a prospective, observational cohort study. A total of 102 patients with HMs admitted to ICU from January 2008 to April 2011 were included. Univariate and multivariate logistic regressions were used to identify factors associated with hospital mortality. During the study period, 3,776 patients with HM were admitted to the Department of Hematology of the Instituto Nacional de Cancerología located in Mexico City, Mexico. After being evaluated by the intensivist, 102 (2.68 %) patients were admitted to the ICU. The ICU mortality rates for patients who had two or less organ system failures and for those with three or more organ system dysfunctions were 20 % (5/25) and 70.1 % (54/77), respectively (P < 0.0001). A multivariate analysis identified independent prognostic factors of in-hospital death as neutropenia at the time of ICU admission (odds ratio (OR), 4.24; 95 % confidence interval (CI), 1.36-13.19, P = 0.012), the need for vasopressors (OR, 4.49; 95 % CI, 1.07-18.79, P = 0.040), need for invasive mechanical ventilation (OR, 4.49; 95 % CI, 1.07-18.79, P = 0.040), and serum creatinine >106 µmol/L (OR, 3.21; 95 % CI, 1.05-9.85, P = 0.041). The ICU and hospital mortality rates were 46.1 and 57.8 %, respectively. The independent prognostic factors of in-hospital death were the need for invasive mechanical ventilation, the need for vasopressors, serum creatinine >106 µmol/L, and neutropenia at the time of ICU admission.


Asunto(s)
Enfermedad Crítica , Neoplasias Hematológicas/diagnóstico , Adulto , Algoritmos , Estudios de Cohortes , Enfermedad Crítica/epidemiología , Enfermedad Crítica/mortalidad , Enfermedad Crítica/terapia , Femenino , Neoplasias Hematológicas/epidemiología , Neoplasias Hematológicas/mortalidad , Mortalidad Hospitalaria , Humanos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Masculino , México/epidemiología , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto , Pronóstico , Respiración Artificial/estadística & datos numéricos
2.
J Clin Neurosci ; 111: 39-45, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-36934658

RESUMEN

BACKGROUND: The burden of having neurologic symptoms (NS) in cancer patients has scantly been studied; therefore, we performed a study whose purpose was to measure the impact of having clinically active (NS) on the quality of life (QoL) of non-primary CNS cancer patients. METHODS: Patients with systemic cancer (non-primary CNS cancer) sent for neurological evaluation at a single cancer center (INCAN) were prospectively invited to respond the EORTC-QLQ-C30 and BN20 questionnaires. Associations of the questionnairés items were blindly measured for the following groups: NS+ or not (NS-) and having active cancer (AC+) or not (AC-). RESULTS: Of 205 patients aged 55.4 ± 15.4 years, 122 (60%) had NS+ and 107 (52%) AC +. The NS+ group (compared with the NS-) showed a significant worse perception in the following scales/items of the EORTC QLQ-C30: physical functioning (median 86 vs. 92, P = 0.012), role functioning (66 vs. 100, P < 0.001), emotional functioning (75 vs. 83, P = 0.005), cognitive functioning (66 vs. 83, P < 0.001), fatigue (33 vs. 22, P < 0.001), nausea and vomiting (P = 0.021), pain (33 vs. 16, P < 0.001), insomnia (33 vs. 0, P = 0.011), appetite loss (P = 0.021), and global health (66 vs. 75, P = 0.001). CONCLUSION: In patients with systemic (non-CNS) cancer, the QoL is significantly worse for patients with active neurologic symptoms.


Asunto(s)
Neoplasias , Calidad de Vida , Humanos , Calidad de Vida/psicología , Neoplasias/complicaciones , Dolor/complicaciones , Náusea , Vómitos , Encuestas y Cuestionarios
3.
World J Crit Care Med ; 4(3): 258-64, 2015 Aug 04.
Artículo en Inglés | MEDLINE | ID: mdl-26261778

RESUMEN

AIM: To describe the intensive care unit (ICU) outcomes of critically ill cancer patients with Acinetobacter baumannii (AB) infection. METHODS: This was an observational study that included 23 consecutive cancer patients who acquired AB infections during their stay at ICU of the National Cancer Institute of Mexico (INCan), located in Mexico City. Data collection took place between January 2011, and December 2012. Patients who had AB infections before ICU admission, and infections that occurred during the first 2 d of ICU stay were excluded. Data were obtained by reviewing the electronic health record of each patient. This investigation was approved by the Scientific and Ethics Committees at INCan. Because of its observational nature, informed consent of the patients was not required. RESULTS: Throughout the study period, a total of 494 critically ill patients with cancer were admitted to the ICU of the INCan, 23 (4.6%) of whom developed AB infections. Sixteen (60.9%) of these patients had hematologic malignancies. Most frequent reasons for ICU admission were severe sepsis or septic shock (56.2%) and postoperative care (21.7%). The respiratory tract was the most frequent site of AB infection (91.3%). The most common organ dysfunction observed in our group of patients were the respiratory (100%), cardiovascular (100%), hepatic (73.9%) and renal dysfunction (65.2%). The ICU mortality of patients with 3 or less organ system dysfunctions was 11.7% (2/17) compared with 66.6% (4/6) for the group of patients with 4 or more organ system dysfunctions (P = 0.021). Multivariate analysis identified blood lactate levels (BLL) as the only variable independently associated with in-ICU death (OR = 2.59, 95%CI: 1.04-6.43, P = 0.040). ICU and hospital mortality rates were 26.1% and 43.5%, respectively. CONCLUSION: The mortality rate in critically ill patients with both HM, and AB infections who are admitted to the ICU is high. The variable most associated with increased mortality was a BLL ≥ 2.6 mmol/L in the first day of stay in the ICU.

4.
Oncol Lett ; 9(4): 1873-1876, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25789059

RESUMEN

The aim of the present study was to observe the incidence of organ dysfunction and the intensive care unit (ICU) outcomes of critically ill cancer patients during the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy post-operative period. The present study included 25 critically ill cancer patients admitted to the ICU of the National Cancer Institute (Mexico City, Mexico) between January 2007 and February 2013. The incidence of organ dysfunction was 68% and patients exhibiting ≤1 organ system dysfunction during ICU admittance remained in hospital for a significantly shorter period compared with patients who exhibited ≥2 organ system dysfunctions (12.4±10.7 vs. 24.1±12.8 days; P=0.025). Therefore, the present study demonstrated that a high incidence of organ dysfunction was associated with a longer ICU hospital stay.

5.
Nutr Hosp ; 30(1): 183-7, 2014 Jul 01.
Artículo en Inglés, Español | MEDLINE | ID: mdl-25137279

RESUMEN

INTRODUCTION: There is currently little information regarding the incidence of hypomagnesaemia and its impact on the prognosis of critically ill patients with haematological malignancies. OBJECTIVE: This study sought to describe the incidence of hypomagnesaemia in critically ill patients with haematological malignancies admitted to an oncological intensive care unit (ICU). METHODS: A total of 102 critically ill patients with haematological malignancies, who were 18 years of age and admitted to the ICU between January 2008 and April 2011, were included in this study. Hypomagnesaemia was defined as a serum magnesium concentration below 1.7 mg/dl. RESULTS: The incidence of hypomagnesaemia at admission or during the first 24 hours of stay in the ICU was 22.5% (23/102). The hospital mortality rates of patients with and without hypomagnesaemia were 47.8% and 60.7%, respectively. CONCLUSION: The incidence of hypomagnesaemia in critically ill patients with haematological malignancies was 22.5%. Mortality in the ICU and in the hospital was similar in patients with and without hypomagnesaemia.


INTRODUCCIÓN: En la actualidad existe poca información relacionada con la incidencia de hipomagnesemia y su impacto en el pronóstico de pacientes hematológicos críticamente enfermos. OBJETIVO: Describir la incidencia de hipomagnesemia en pacientes hematológicos ingresados a en una unidad de cuidados intensivos (UCI) oncológica. MÉTODOS: Se incluyeron 102 pacientes con enfermedad hematológica, mayores de 18 años, ingresados en la UCI entre enero 2008 y abril 2011. Se definió hipomagnesemia como concentración sérica de magnesio inferior a 1,7 mg/dl. RESULTADOS: La incidencia de hipomagnesemia al ingreso o durante las primeras 24 horas de estancia en la UCI fue del 22,5% (23/102). La mortalidad hospitalaria de los enfermos con y sin hipomagnesemia fue del 47,8% y 60,7%, respectivamente. CONCLUSIÓN: La incidencia de hipomagnesemia en pacientes hematológicos críticamente enfermos fue del 22,5%. La mortalidad en UCI y en el hospital fue similar en los enfermos con y sin hipomagnesemia.


Asunto(s)
Neoplasias Hematológicas/complicaciones , Magnesio/metabolismo , Enfermedades Metabólicas/etiología , Adulto , Enfermedad Crítica , Femenino , Neoplasias Hematológicas/mortalidad , Mortalidad Hospitalaria , Humanos , Incidencia , Masculino , Enfermedades Metabólicas/epidemiología , Persona de Mediana Edad , Estudios Prospectivos
6.
Am J Hosp Palliat Care ; 30(1): 7-11, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22363042

RESUMEN

PURPOSE: To assess the characteristics of critically ill patients with gynecological cancer, and to evaluate their prognosis. METHODS: Fifty-two critically ill patients with gynecological cancer admitted to intensive care unit (ICU) were included. Univariate and multivariate logistic regressions were used to identify factors associated with hospital mortality. RESULTS: Thirty-five patients (67.3%) had carcinoma of the cervix uteri and 11 (21.2%) had ovarian cancer. The mortality rate in the ICU was 17.3% (9 of 52) and hospital mortality rate were 23%(12 of 52). In the multivariate analysis, independent prognostic factors for hospital mortality were vasopressor use (odds ratio [OR] = 8.60, 95% confidence interval [CI] 2.05-36; P = .03) and the Acute Physiology and Chronic Health Evaluation (APACHE) II score (OR = 1.43, 95% CI 1.01-2.09; P = .048). CONCLUSIONS: The independent prognostic factors for hospital mortality were the need for vasopressors and the APACHE II score.


Asunto(s)
Enfermedad Crítica/mortalidad , Neoplasias de los Genitales Femeninos/mortalidad , Mortalidad Hospitalaria , Unidades de Cuidados Intensivos/estadística & datos numéricos , APACHE , Adulto , Anciano , Enfermedad Crítica/epidemiología , Femenino , Neoplasias de los Genitales Femeninos/epidemiología , Humanos , Tiempo de Internación , Persona de Mediana Edad , Pronóstico , Factores de Riesgo , Tasa de Supervivencia , Resultado del Tratamiento
7.
Case Rep Med ; 2011: 647528, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22110513

RESUMEN

Influenza B virus infections are less common than infections caused by influenza A virus in critically ill patients, but similar mortality rates have been observed for both influenza types. Pneumonia caused by influenza B virus is uncommon and has been reported in pediatric patients and previously healthy adults. Critically ill patients with pneumonia caused by influenza virus may develop acute respiratory distress syndrome. We describe the clinical course of a critically ill patient with diffuse large B-cell lymphoma nongerminal center B-cell phenotype who developed acute respiratory distress syndrome caused by influenza B virus infection. This paper emphasizes the need to suspect influenza B virus infection in critically ill immunocompromised patients with progressive deterioration of cardiopulmonary function despite treatment with antibiotics. Early initiation of neuraminidase inhibitor and the implementation of guidelines for management of severe sepsis and septic shock should be considered.

8.
Am J Hosp Palliat Care ; 28(4): 253-7, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21057142

RESUMEN

PURPOSE: The aim of this study was to investigate the incidence of hypoalbuminemia in critically ill patients with cancer and to describe the relationship of serum albumin levels to mortality. DESIGN: An observational cohort study. There were no interventions. RESULTS: During the study period, 200 patients were eligible for inclusion. A total of 164 (82%) patients had a serum albumin concentration below 35 g/L, of which 91 (55.5%) patients had levels of albumin ≤20 g/L. The mean serum albumin was 18.17 g/L. The crude mortality rate was 22.5%. The highest mortality rate (73%) was seen in the group of patients whose serum albumin levels were <20 g/L. CONCLUSION: The incidence of hypoalbuminemia in critically ill patients with cancer admitted to ICU was high.


Asunto(s)
Enfermedad Crítica , Hipoalbuminemia/complicaciones , Hipoalbuminemia/mortalidad , Unidades de Cuidados Intensivos/estadística & datos numéricos , Neoplasias/complicaciones , Adulto , Anciano , Femenino , Humanos , Incidencia , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad
10.
Am J Hosp Palliat Care ; 26(5): 341-6, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19357377

RESUMEN

The aim of the current study was to describe the utility of the Sequential Organ Failure Assessment score in assessing the severity of organ dysfunction in patients with cancer before admission to the intensive care unit. This was a prospective cohort study performed from January to October 2007. The Sequential Organ Failure Assessment score was recorded before admission to intensive care unit. Two hundred patients were included. The Sequential Organ Failure Assessment score of patients having survived the intensive care unit stay was 3.44 +/- 3.56 and of the patients no survivor's was 9.35 +/- 3.45. There were 89.5% of the patients who had 2 or more organ dysfunctions. The area under the receiver operating characteristic curve for score Sequential Organ Failure Assessment was 0.87. The mortality in the intensive care unit was 27.5%. The Sequential Organ Failure Assessment score was predictive for survival in intensive care unit when applied before admission.


Asunto(s)
Unidades de Cuidados Intensivos , Insuficiencia Multiorgánica/diagnóstico , Neoplasias/terapia , Índice de Severidad de la Enfermedad , Femenino , Humanos , Unidades de Cuidados Intensivos/organización & administración , Modelos Logísticos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Curva ROC
11.
Nutr. hosp ; 30(1): 184-187, jul. 2014. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-143760

RESUMEN

Introducción: En la actualidad existe poca información relacionada con la incidencia de hipomagnesemia y su impacto en el pronóstico de pacientes hematológicos críticamente enfermos. Objetivo: Describir la incidencia de hipomagnesemia en pacientes hematológicos ingresados a en una unidad de cuidados intensivos (UCI) oncológica. Métodos: Se incluyeron 102 pacientes con enfermedad hematológica, mayores de 18 años, ingresados en la UCI entre enero 2008 y abril 2011. Se definió hipomagnesemia como concentración sérica de magnesio inferior a 1,7 mg/dl. Resultados: La incidencia de hipomagnesemia al ingreso o durante las primeras 24 horas de estancia en la UCI fue del 22,5% (23/102). La mortalidad hospitalaria de los enfermos con y sin hipomagnesemia fue del 47,8% y 60,7%, respectivamente. Conclusión: La incidencia de hipomagnesemia en pacientes hematológicos críticamente enfermos fue del 22,5%. La mortalidad en UCI y en el hospital fue similar en los enfermos con y sin hipomagnesemia (AU)


Introduction: There is currently little information regarding the incidence of hypomagnesaemia and its impact on the prognosis of critically ill patients with haematological malignancies. Objective: This study sought to describe the incidence of hypomagnesaemia in critically ill patients with haematological malignancies admitted to an oncological intensive care unit (ICU). Methods: A total of 102 critically ill patients with haematological malignancies, who were 18 years of age and admitted to the ICU between January 2008 and April 2011, were included in this study. Hypomagnesaemia was defined as a serum magnesium concentration below 1.7 mg/dl. Results: The incidence of hypomagnesaemia at admission or during the first 24 hours of stay in the ICU was 22.5% (23/102). The hospital mortality rates of patients with and without hypomagnesaemia were 47.8% and 60.7%, respectively. Conclusion: The incidence of hypomagnesaemia in critically ill patients with haematological malignancies was 22.5%. Mortality in the ICU and in the hospital was similar in patients with and without hypomagnesaemia (AU)


Asunto(s)
Humanos , Deficiencia de Magnesio/epidemiología , Enfermedades Hematológicas/complicaciones , Cuidados Críticos/métodos , Enfermedad Crítica , Unidades de Cuidados Intensivos/estadística & datos numéricos
12.
Rev. invest. clín ; 48(1): 55-8, ene.-feb. 1996. tab
Artículo en Español | LILACS | ID: lil-180639

RESUMEN

Se informa la primera experiencia mexicana con el uso de factor estimulante de colonia granulocito-macrófago (GM-CSF) com profilaxis de la neutropenia secundaria a ganciclovir, en la prevención de la enfermedad por citomegalovirus (CMV) en un paciente CMV sero-positivo con leucemia mieloide aguda en primera remisión, trasplantando con donador HLA idéntico y CMV sero-positivo. La toma de injerto ocurrió el día 14. Se inició ganciclovir 5 mg/kg/3 veces por semana) en el día 35 acompañandose de toxicidad medular secundaria 28 días después con neutropenia grave que remitió de manera espontánea posterior a la suspensión del mismo. A fin de concluir el esquema de profilaxis, se inició GM-CSF a dosis de 300 mg/kg/día concomitante al ganciclovir a dosis de 5 mg/kg/día con lo cual fue posible conluir tratamiento sin que se reindujera toxicidad medular. No hubo evidencia de enfermedad de injerto contra huésped ni de infección por CMV. La evolución del paciente fue satisfactoria durante un año, posterior al cual, presentó recaída de su enfermedad de base mueriendo por complicaciones secundarias a leucemia


Asunto(s)
Humanos , Masculino , Adulto , Trasplante de Médula Ósea , Ganciclovir/efectos adversos , Ganciclovir/toxicidad , Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Leucemia Mieloide/complicaciones , Leucemia Mieloide/virología , Neutropenia/inducido químicamente , Neutropenia/terapia , Trasplante Autólogo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA